Jeremiah L. Oyer
Tayler J. Croom-Perez
Md Faqrul Hasan
Javier A. Rivera-Huertas
Sarah B. Gitto†
Joanna M. Mucha†Xiang Zhu
Deborah A. Altomare
Robert Y. Igarashi†
Alicja J. Copik*- Burnett School of Biomedical Science, College of Medicine, University of Central Florida, Orlando, FL, United States
by Oyer JL, Croom-Perez TJ, Hasan MF, Rivera-Huertas JA, Gitto SB, Mucha JM, Zhu X, Altomare DA, Igarashi RY and Copik AJ (2024). Front. Immunol. 15:1383281. doi: 10.3389/fimmu.2024.1383281
In the published article, there was an error in the Funding statement. A funding source was mistakenly not acknowledged in the publication. The correct Funding statement appears below.
“The author(s) declare financial support was received for the research, authorship, and/or publication of this article. We would like to thank The Guillot-Henley Family AML Research Fund In Loving Memory of William L. Guillot fund, the FL DOH James and Ester King Program (Grant No. 9JK04), Bankhead-Coley Biomedical Research Program (3BN02, 4BB06) and the Live Like Bella Pediatric Cancer Research Initiative (22L04) as well as the University of Central Florida Preeminent Postdoctoral Program for funding. The authors declare that this study received funding from Kiadis Pharma, a Sanofi company. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: natural killer cell, NK cell therapy, memory-like NK cells, immunotherapy, adoptive cell therapy
Citation: Oyer JL, Croom-Perez TJ, Hasan MF, Rivera-Huertas JA, Gitto SB, Mucha JM, Zhu X, Altomare DA, Igarashi RY and Copik AJ (2025) Correction: PM21-particle stimulation augmented with cytokines enhances NK cell expansion and confers memory-like characteristics with enhanced survival. Front. Immunol. 16:1650274. doi: 10.3389/fimmu.2025.1650274
Received: 19 June 2025; Accepted: 20 June 2025;
Published: 04 July 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Oyer, Croom-Perez, Hasan, Rivera-Huertas, Gitto, Mucha, Zhu, Altomare, Igarashi and Copik. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Alicja J. Copik, QWxpY2phLkNvcGlrQHVjZi5lZHU=
†Present address: Sarah B. Gitto, Department of Pathology and Laboratory Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
Joanna M. Mucha, Department of Physiological Sciences, Institute of Veterinary Medicine, Warsaw University of Life Sciences, Warszawa, Poland
Robert Y. Igarashi, Kiadis Pharma, a Sanofi Company, Sanofi Oncology, Amsterdam, Netherlands